oxaprozin Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
2013 21256-18-8

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • oxaprozin
  • alvo
  • oxaprozin potassium
  • WY 21743
An oxazole-propionic acid derivative, cyclooxygenase inhibitor, and non-steroidal anti-inflammatory drug that is used in the treatment of pain and inflammation associated with of OSTEOARTHRITIS; RHEUMATOID ARTHRITIS; and ARTHRITIS, JUVENILE.
  • Molecular weight: 293.32
  • Formula: C18H15NO3
  • CLOGP: 2.95
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 1
  • TPSA: 63.33
  • ALOGS: -3.96
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.90 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 1.70 mg/mL Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.50 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 88.64 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 98 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

DateAgencyCompanyOrphan
Oct. 29, 1992 FDA GD SEARLE

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 485.90 21.48 237 2135 243588 46440102
Emotional distress 22.85 21.48 16 2356 30691 46652999

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Drug hypersensitivity 93.00 31.62 37 478 68482 29883481

Pharmacologic Action:

SourceCodeDescription
ATC M01AE12 MUSCULO-SKELETAL SYSTEM
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
Propionic acid derivatives
FDA CS M0001335 Anti-Inflammatory Agents, Non-Steroidal
FDA MoA N0000000160 Cyclooxygenase Inhibitors
FDA EPC N0000175722 Nonsteroidal Anti-inflammatory Drug
MeSH PA D000700 Analgesics
MeSH PA D018712 Analgesics, Non-Narcotic
MeSH PA D000893 Anti-Inflammatory Agents
MeSH PA D000894 Anti-Inflammatory Agents, Non-Steroidal
MeSH PA D018501 Antirheumatic Agents
MeSH PA D016861 Cyclooxygenase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D018689 Sensory System Agents
CHEBI has role CHEBI:35475 non-steroidal anti-inflammatory drugs

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Rheumatoid arthritis indication 69896004 DOID:7148
Osteoarthritis indication 396275006
Juvenile rheumatoid arthritis indication 410795001
Ankylosing spondylitis off-label use 9631008 DOID:7147
Peptic ulcer contraindication 13200003 DOID:750
Myocardial infarction contraindication 22298006 DOID:5844
Hypertensive disorder contraindication 38341003 DOID:10763
Gastrointestinal ulcer contraindication 40845000
Chronic heart failure contraindication 48447003
Disorder of cardiovascular system contraindication 49601007 DOID:1287
Hepatic failure contraindication 59927004
Blood coagulation disorder contraindication 64779008 DOID:1247
Gastrointestinal hemorrhage contraindication 74474003
Kidney disease contraindication 90708001 DOID:557
Coronary artery bypass graft contraindication 232717009
Pregnancy, function contraindication 289908002
Cardiovascular event risk contraindication 395112001
Smokes tobacco daily contraindication 449868002

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 4.51 acidic
pKa2 0.69 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Prostaglandin G/H synthase 1 Enzyme INHIBITOR IC50 6.07 DRUG MATRIX CHEMBL
Prostaglandin G/H synthase 2 Enzyme INHIBITOR IC50 4.44 IUPHAR CHEMBL
fMet-Leu-Phe receptor GPCR WOMBAT-PK

External reference:

IDSource
4020735 VUID
N0000148313 NUI
D00463 KEGG_DRUG
174064-08-5 SECONDARY_CAS_RN
4020735 VANDF
C0069739 UMLSCUI
CHEBI:7822 CHEBI
CHEMBL1071 ChEMBL_ID
CHEMBL1200463 ChEMBL_ID
4614 PUBCHEM_CID
D000077431 MESH_DESCRIPTOR_UI
DB00991 DRUGBANK_ID
7252 IUPHAR_LIGAND_ID
3458 INN_ID
MHJ80W9LRB UNII
32613 RXNORM
41102 MMSL
5210 MMSL
d00853 MMSL
004113 NDDF
108518005 SNOMEDCT_US
386031002 SNOMEDCT_US
427736002 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Daypro HUMAN PRESCRIPTION DRUG LABEL 1 0025-1381 TABLET, FILM COATED 600 mg ORAL NDA 30 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 0093-0924 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 0185-0141 TABLET 600 mg ORAL ANDA 29 sections
OXAPROZIN HUMAN PRESCRIPTION DRUG LABEL 1 16590-178 TABLET 600 mg ORAL ANDA 24 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 21695-100 TABLET, FILM COATED 600 mg ORAL ANDA 27 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 52959-800 TABLET, FILM COATED 600 mg ORAL ANDA 23 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 54868-4548 TABLET 600 mg ORAL ANDA 16 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 55111-170 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
Daypro HUMAN PRESCRIPTION DRUG LABEL 1 55289-453 TABLET, FILM COATED 600 mg ORAL NDA 30 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 55289-601 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 59762-6002 TABLET, FILM COATED 600 mg ORAL NDA AUTHORIZED GENERIC 30 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 60760-092 TABLET 600 mg ORAL ANDA 28 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 60760-203 TABLET 600 mg ORAL ANDA 30 sections
OXAPROZIN HUMAN PRESCRIPTION DRUG LABEL 1 61919-178 TABLET 600 mg ORAL ANDA 21 sections
OXAPROZIN HUMAN PRESCRIPTION DRUG LABEL 1 61919-673 TABLET 600 mg ORAL ANDA 21 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 63629-1345 TABLET, FILM COATED 600 mg ORAL ANDA 28 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 66336-722 TABLET 600 mg ORAL ANDA 25 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 68151-0523 TABLET 600 mg ORAL ANDA 29 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 69238-1120 TABLET 600 mg ORAL ANDA 28 sections
OXAPROZIN HUMAN PRESCRIPTION DRUG LABEL 1 70332-310 TABLET, FILM COATED 600 mg ORAL ANDA 20 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 70332-311 TABLET 600 mg ORAL ANDA 27 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 71335-0617 TABLET 600 mg ORAL ANDA 28 sections
Oxaprozin HUMAN PRESCRIPTION DRUG LABEL 1 71335-0902 TABLET 600 mg ORAL ANDA 28 sections
OXAPROZIN HUMAN PRESCRIPTION DRUG LABEL 1 72189-077 TABLET 600 mg ORAL ANDA 16 sections